5-hydroxy-4-methoxy-5-(1-methylethenyl)-2-furanone has been researched along with Osteogenic Sarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vansteelandt, M | 1 |
| Blanchet, E | 1 |
| Egorov, M | 1 |
| Petit, F | 1 |
| Toupet, L | 1 |
| Bondon, A | 1 |
| Monteau, F | 1 |
| Le Bizec, B | 1 |
| Thomas, OP | 1 |
| Pouchus, YF | 1 |
| Le Bot, R | 1 |
| Grovel, O | 1 |
1 other study available for 5-hydroxy-4-methoxy-5-(1-methylethenyl)-2-furanone and Osteogenic Sarcoma
| Article | Year |
|---|---|
Ligerin, an antiproliferative chlorinated sesquiterpenoid from a marine-derived Penicillium strain.
Topics: Antineoplastic Agents; Cyclohexanes; Drug Screening Assays, Antitumor; Estuaries; Fatty Acids, Unsat | 2013 |